<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692664</url>
  </required_header>
  <id_info>
    <org_study_id>TAILOR</org_study_id>
    <nct_id>NCT02692664</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft</brief_title>
  <acronym>TAILOR</acronym>
  <official_title>Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JOTEC GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JOTEC GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients will be observed who receive an E-liac Stent Graft for treatment of&#xD;
      isolated iliac aneurysms or an E-liac Stent Graft in combination with one of the following&#xD;
      AAA stent grafts: E-tegra Stent Graft, Endurant AAA Stent Graft, Zenith AAA Endovascular&#xD;
      Graft, Gore Excluder AAA Endoprosthesis for treatment of aorto-iliac aneurysms.&#xD;
&#xD;
      Objectives of this post-market registry are:&#xD;
&#xD;
      Primary: To prevent the risk of rupture and death by the treatment of common iliac aneurysm&#xD;
      with an iliac branched stent graft (E-liac, JOTEC) Secondary: Evaluation of safety and&#xD;
      feasibility of the E-liac Stent Graft System used in endovascular treatment of uni- or&#xD;
      bilateral aorto-iliac or iliac aneurysm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>30 days follow-up</time_frame>
    <description>Clinical success related to the E-liac Stent Graft combines the following criteria (adapted from Chaikof 2002):&#xD;
Clinical success should be reported on an intent-to-treat Basis&#xD;
requires successful deployment of the E-liac Stent Graft at the intended location without&#xD;
Death as a result of iliac aneurysm-related treatment&#xD;
Type I or III endoleak&#xD;
E-liac Stent Graft infection&#xD;
E-liac Stent Graft thrombosis (including internal iliac artery thrombosis)&#xD;
Aneurysm growth &gt;3mm in maximum diameter for common iliac aneurysm and &gt;5mm in maximum diameter for aortic aneurysm at 12, 24, and 36 months follow-up&#xD;
Common iliac aneurysm rupture&#xD;
Conversion to open repair&#xD;
Failure of E-liac Stent Graft integrity</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Iliac Aneurysm</condition>
  <condition>AAA</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular aorto-iliac repair</intervention_name>
    <other_name>EVAR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with unilateral or bilateral common iliac aneurysm, treated with&#xD;
        the E-liac Stent Graft System&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral or bilateral aorto-iliac or iliac aneurysm&#xD;
&#xD;
          -  Suitable for endovascular repair&#xD;
&#xD;
          -  Patient must be compliant with life- long follow-up investigations&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  lliac/femoral access vessel morphology compatible with the implantation procedure and&#xD;
             the 18Fr (6mm OD) delivery system&#xD;
&#xD;
          -  Non-aneurysmal common iliac artery landing area in case of iliac artery aneurysm ≥&#xD;
             20mm&#xD;
&#xD;
          -  Diameter of the common iliac artery in the proximal landing area: 12mm to 17mm&#xD;
&#xD;
          -  Non-aneurysmal external iliac artery segment distal to the aneurysm ≥15mm&#xD;
&#xD;
          -  Diameter of the external iliac artery in the distal landing area: 8mm to 13mm&#xD;
&#xD;
          -  Non-aneurysmal internal iliac artery segment distal to the aneurysm ≥15mm&#xD;
&#xD;
          -  Angle between external iliac artery and internal iliac artery ≤50°&#xD;
&#xD;
          -  Thrombus free iliac lumen in the area of iliac bifurcation to open hypogastric side&#xD;
             branch and to implant covered stent ≥18mm&#xD;
&#xD;
          -  Sufficiently open internal iliac arterv ostium&#xD;
&#xD;
          -  Patients must comply with the instructions for use.&#xD;
&#xD;
          -  Patients with common iliac aneurysm with a diameter ≥30mm when isolated or common&#xD;
             iliac aneurysm with a diameter &gt;25mm when associated with an abdominal aortic aneurysm&#xD;
&#xD;
          -  Unilateral or bilateral common iliac aneurysm&#xD;
&#xD;
          -  Patient's anatomy must be fit for stent graft placement on preoperative angio CT scan.&#xD;
&#xD;
          -  Patient is affiliated to the social security or equivalent system.&#xD;
&#xD;
          -  The patient must be available for the appropriate follow-up times for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Patient has been informed of the nature of the study, agrees to its provisions and has&#xD;
             signed the informed consent from.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not meet the instructions for use&#xD;
&#xD;
          -  Patients with one of the contraindications as indicated in the instructions for use&#xD;
&#xD;
          -  Patients with a stenotic internal iliac ostium of &lt; 4mm in Diameter&#xD;
&#xD;
          -  Patients with severe internal iliac atherosclerosis&#xD;
&#xD;
          -  Patients that do not have a suitable landing area in the main stem of the IIA (maximum&#xD;
             diameter in landing area &lt;12mm)&#xD;
&#xD;
          -  Patients with pseudoaneurysms&#xD;
&#xD;
          -  Patients with symptomatic and ruptured iliac aneurysms&#xD;
&#xD;
          -  Patients pretreated with a AAA stent graft or a bifurcated vascular graft&#xD;
&#xD;
          -  Patient with thrombocytopenia&#xD;
&#xD;
          -  Patient with an estimated glomerular filtration rate &lt; 30 ml/min/1,73m2 immediately&#xD;
             before the Intervention&#xD;
&#xD;
          -  Female of child bearing potential&#xD;
&#xD;
          -  In the lnvestigator's opinion patient has (a) eo-morbid condition(s) that could limit&#xD;
             the patient's ability to participate in the study, compliance with follow-up&#xD;
             requirements, or impact the scientific integrity of the study&#xD;
&#xD;
          -  Patient is currently participating in an investigational drug or device study that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints&#xD;
&#xD;
          -  Patient with malignancy needing chemotherapy or radiation&#xD;
&#xD;
          -  Patients with life expectancy of less than 36 months&#xD;
&#xD;
          -  Patient minor or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrien Kaladji, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iliac side branch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Iliac Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

